Almirall exercises option with Dermira to license rights to lebrikizumab in Europe
Almirall and Dermira announced that Almirall has exercised its option to license rights to develop and commercialize lebrikizumab for treatment of atopic dermatitis and certain other indications in Europe. Almirall will pay Dermira $50 million and Dermira will be eligible to milestones. June 25, 2019